Number of shares and voting rights of Innate Pharma as at May 1, 2020
First patient dosed in avdoralimab Phase II clinical trial in COVID-19 patients with severe pneumonia
Innate Pharma files its 2019 Universal Registration Document (Document d'enregistrement universel) and its 2019 annual report on Form 20-F
Innate Pharma to hold its Annual General Meeting of shareholders on May 19, 2020 without the physical presence of its shareholders
Innate Pharma reports Full Year 2019 financial results and business update
First patient dosed in IPH5201 Phase I clinical trial in advanced solid tumors
French regulatory agency agrees lacutamab TELLOMAK trial can resume recruitment in Sezary syndrome and mycosis fungoides
Innate Pharma provides update from regulatory agencies on lacutamab TELLOMAK trial
The European Medicines Agency accepts the regulatory submission for Lumoxiti in relapsed or refractory hairy cell leukemia
Innate Pharma provides update on lacutamab TELLOMAK trial
